SCHEMBL2706337

SCHEMBL2706337

CCOC(=O)/C=C/c1ccc(Nc2nc(-c3cccnc3)cs2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 11/20 0.64
KMT2A Q03164 11/20 0.64
RAB9A P51151 11/20 0.64
NPC1 O15118 9/20 0.64
GAA P10253 3/20 0.59
PKM P14618 1/20 0.59
VCP P55072 1/20 0.59
CASP3 P42574 2/20 0.58
SENP8 Q96LD8 2/20 0.58
SENP7 Q9BQF6 2/20 0.58
SENP6 Q9GZR1 2/20 0.58
HDAC3 O15379 1/20 0.56
ABL1 P00519 1/20 0.56
PDGFRB P09619 1/20 0.56
BCR P11274 1/20 0.56
KDR P35968 1/20 0.56
HDAC4 P56524 1/20 0.56
HDAC1 Q13547 1/20 0.56
HDAC7 Q8WUI4 1/20 0.56
HDAC2 Q92769 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL206757 0.85 RAB9A (0.70) MEN1KMT2ARAB9ANPC1GAA
SCHEMBL206756 0.85 RAB9A (0.70) MEN1KMT2ARAB9ANPC1GAA
SCHEMBL206904 0.83 MEN1 (0.67) MEN1KMT2ARAB9ANPC1GAA
SCHEMBL4579101 0.83 RAB9A (0.71) MEN1KMT2ARAB9ANPC1GAA
SCHEMBL23647330 0.81 MAPT (0.56) MEN1KMT2ARAB9ANPC1PKM
SCHEMBL206486 0.78 MEN1 (0.76) MEN1KMT2ARAB9ANPC1GAA
SCHEMBL208387 0.77 RAB9A (0.58) MEN1KMT2ARAB9ANPC1GAA
SCHEMBL4429689 0.77 ABL1 (0.56) MEN1KMT2ARAB9ANPC1GAA
SCHEMBL4429688 0.77 ABL1 (0.56) MEN1KMT2ARAB9ANPC1GAA
SCHEMBL206539 0.76 SMN1; SMN2 (0.77) MEN1KMT2ARAB9ANPC1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE PIGS, CPT1A, SLC10A1 MEN1 3862/4885KMT2A 3476/4885RAB9A 1357/4885
US-20070004711-A1 Thiazole compounds and methods of use PIGS, CPT1A, SLC10A1 MEN1 3862/4885KMT2A 3476/4885RAB9A 1357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.